Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion
April 28 : AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S. drugmaker Eli Lilly worth up to $2.25 billion to develop AI-designed enzymes for genetic medicines.Here are some details: • Under the agreement, Profluent will use its artificial intelligence t
28 Apr 11:18 · CNA